Laura Tadvalkar

Laura Tadvalkar has a wealth of work experience in the venture capital and biopharmaceutical industries. Laura started their career in 2018 as a Kauffman Fellow, Class 23, with the Kauffman Fellows. In 2020, they began working at RA Capital as a Principal and Venture Senior Associate. Laura also served as a Board Observer for PepGen, Aerovate Therapeutics, Inc., and Mariana Oncology that same year. In 2021, they became a Board Director for Expansion Therapeutics, Hemab Therapeutics, Aliada Therapeutics, and Stealth NewCo, and a Former Board Observer for Be Biopharma.

Laura Tadvalkar attended Yale University from 2005 to 2009, where they earned a BS (Intensive) cum laude in Chemistry with distinction in the major. Laura then went on to Harvard University from 2009 to 2014, where they earned a Doctor of Philosophy (Ph.D.) in Chemical Biology.